-+ 0.00%
-+ 0.00%
-+ 0.00%

Sangamo Therapeutics Data From Phase 1/2 STAAR Trial Evaluating Isaralgagene Civaparvovec Shows Positive Mean Annualized Estimated Glomerular Filtration Rate Slope At 52 Weeks

Benzinga·02/03/2026 21:25:34
Listen to the news

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

These data will be presented via four platform presentations and in poster presentations at the 22nd Annual WORLDSymposiumTM taking place in San Diego, CA, February 2-6, 2026. These data will also be available on Sangamo's website on the Presentations page.